News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,946 Results
Type
Article (9186)
Company Profile (49)
Press Release (258711)
Section
Business (74192)
Career Advice (357)
Deals (16422)
Drug Delivery (35)
Drug Development (40899)
Employer Resources (29)
FDA (7498)
Job Trends (5636)
News (140242)
Policy (13240)
Tag
Academia (711)
Alliances (18468)
Alzheimer's disease (596)
Approvals (7472)
Artificial intelligence (67)
Bankruptcy (149)
Best Places to Work (5133)
Biotechnology (47)
Breast cancer (52)
Cancer (628)
Cardiovascular disease (51)
Career advice (313)
CAR-T (44)
Cell therapy (138)
Clinical research (33474)
Collaboration (178)
Compensation (40)
COVID-19 (851)
C-suite (43)
Data (769)
Diabetes (68)
Diagnostics (2539)
Drug pricing (38)
Earnings (35009)
Events (35979)
Executive appointments (125)
FDA (7829)
Funding (154)
Gene therapy (96)
GLP-1 (183)
Government (1454)
Healthcare (7273)
Infectious disease (895)
Inflammatory bowel disease (52)
Interviews (49)
IPO (8610)
Job creations (742)
Job search strategy (272)
Layoffs (45)
Legal (2394)
Lung cancer (86)
Manufacturing (78)
Medical device (5565)
Medtech (5566)
Mergers & acquisitions (7924)
Metabolic disorders (174)
Neuroscience (708)
NextGen Class of 2024 (1893)
Non-profit (914)
Northern California (830)
Obesity (99)
Opinion (74)
Patents (63)
People (17855)
Phase I (10607)
Phase II (14807)
Phase III (11091)
Pipeline (343)
Postmarket research (917)
Preclinical (3924)
Press Release (52)
Radiopharmaceuticals (133)
Rare diseases (97)
Real estate (1503)
Regulatory (9966)
Research institute (665)
Resumes & cover letters (49)
Southern California (668)
Startups (886)
United States (6888)
Vaccines (156)
Weight loss (67)
Date
Today (70)
Last 7 days (316)
Last 30 days (2007)
Last 365 days (19239)
2024 (17642)
2023 (21243)
2022 (26943)
2021 (29003)
2020 (26414)
2019 (17813)
2018 (13211)
2017 (13846)
2016 (11843)
2015 (14237)
2014 (9955)
2013 (7545)
2012 (7760)
2011 (8467)
2010 (7724)
Location
Africa (240)
Arizona (39)
Asia (20195)
Australia (5229)
California (1767)
Canada (765)
China (133)
Colorado (64)
Connecticut (98)
Europe (37080)
Florida (232)
Georgia (53)
Illinois (128)
Indiana (95)
Japan (48)
Maryland (246)
Massachusetts (1306)
Minnesota (77)
New Jersey (671)
New York (549)
North Carolina (335)
Northern California (830)
Ohio (47)
Pennsylvania (445)
South America (360)
Southern California (668)
Texas (246)
Washington State (260)
267,946 Results for "iaso biotherapeutics usa limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Comprehensively Covering Multiple Myeloma: IASO Bio’s GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA
IASO Biotechnology (“IASO Bio”) today announces that the investigational new drug (IND) application for RD118, an independently developed, fully human GPRC5D-targeting chimeric antigen receptor T-cell (CAR-T) therapy, has been approved by the National Medical Products Administration (NMPA) for treatment of relapsed/refractory multiple myeloma (RRMM).
June 28, 2024
·
5 min read
Biotech Bay
IASO Bio Presented Clinical Data and Single-cell Analysis of Equecabtagene Autoleucel for the Treatment of Central Nervous System Autoimmunity in Oral Presentation at EAN Congress 2024
IASO biotechnology presented the clinical data and single-cell analysis of the fully human anti-BCMA CAR T cell therapy for the treatment of central nervous system autoimmunity in an oral presentation at the 2024 European Academy of Neurology Annual Meeting.
July 1, 2024
·
5 min read
Policy
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla).
May 20, 2024
·
3 min read
Biotech Bay
IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma in Oral Presentation at EHA 2024
IASO biotechnology presented clinical data on the use of Equecabtagene Autoleucel, the world’s first approved fully human CAR-T product, for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple myeloma in an oral presentation at the 2024 European Hematology Association Annual Congress.
June 15, 2024
·
5 min read
Biotech Bay
IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies
IASO Biotherapeutics announced a new set of collaborations with Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, for the development and commercialization of novel ex vivo and in vivo cell and gene therapies.
January 3, 2024
·
5 min read
Policy
IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis
IASO Biotechnology is pleased to announce that the Investigational New Drug application for its BCMA CAR-T has been approved by the U.S. Food and Drug Administration for use in U.S. clinical trials for generalised myasthenia gravis.
April 3, 2024
·
5 min read
Policy
IASO Bio Announces NMPA’s IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma
IASO Bio announced that China National Medical Products Administration has approved the Investigational New Drug application for Equecabtagene Autoleucel, a self-developed fully-human anti-B cell maturation antigen chimeric antigen receptor autologous T-cell injection, for an expanded indication in treating relapsed and/or refractory multiple myeloma patients who have undergone 1-2 lines of prior therapies and are refractory to lenalidomide.
March 29, 2024
·
4 min read
Press Releases
Rigaku BioScience Lab Opens in USA
November 21, 2024
·
3 min read
Business
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
Umoja Biopharma, Inc. and IASO Biotherapeutics announced today that they have entered into a research agreement to evaluate Umoja’s iCIL platform with IASO’s best-in-class CARs,
November 21, 2022
·
7 min read
Pharm Country
Biocodex Microbiota Foundation Announces Open Call For 2024 USA Microbiome Research Grant
The Biocodex Microbiota Foundation is announcing the 2024 open call for applications for its annual USA research grant.
June 25, 2024
·
3 min read
1 of 26,795
Next